{"id":449959,"date":"2021-03-03T16:04:19","date_gmt":"2021-03-03T21:04:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449959"},"modified":"2021-03-03T16:04:19","modified_gmt":"2021-03-03T21:04:19","slug":"blossomhill-therapeutics-closes-71m-series-a-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/","title":{"rendered":"BlossomHill Therapeutics Closes $71M Series A Financing"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, March  03, 2021  (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised\u00a0$71 million\u00a0in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company&#8217;s Board of Directors.\u00a0\u00a0<\/p>\n<p>&#8220;Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,\u201d said\u00a0Dr. J. Jean Cui, Co-Founder, President and CEO. &#8220;We are very delighted to have strong support from this group of stellar investors in this Series A round of financing, and to have Bihua, George, and Carl join our Board of Directors.&#8221;<\/p>\n<p>&#8220;We are living in a golden age of bringing precision cancer therapy to patients with actionable mutations. Cormorant is privileged to have the opportunity to partner with Dr Cui again to enable her unique drug design capability to bring powerful innovative medicine to patients in need,&#8221; remarked Bihua Chen, Cormorant Asset Management.<\/p>\n<p>\u201cWe are excited to partner with Peter &amp; Jean, who have strong insight in identifying key clinical needs and addressing them with targeted small molecule drugs,\u201d commented Carl Gordon, OrbiMed Advisors.<\/p>\n<p>Proceeds from the financing will be used to fund the research and development efforts at BlossomHill Therapeutics and advance lead pipeline projects into clinical development. BlossomHill Therapeutics is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Drs. Cui and Li are also the founders of Turning Point Therapeutics, Inc.<\/p>\n<p>\n        <strong>About BlossomHill Therapeutics, Inc.<\/strong><br \/>\n        <br \/>BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D. and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds which include Crizotinib, Lorlatinib, Repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/884724ec-eab9-4fd2-b333-1c1f5db90ae0\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact:\r\ninfo@bhtherapeutics.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised\u00a0$71 million\u00a0in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company&#8217;s Board of Directors.\u00a0\u00a0 &#8220;Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,\u201d said\u00a0Dr. J. Jean Cui, Co-Founder, President and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BlossomHill Therapeutics Closes $71M Series A Financing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-449959","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised\u00a0$71 million\u00a0in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company&#8217;s Board of Directors.\u00a0\u00a0 &#8220;Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,\u201d said\u00a0Dr. J. Jean Cui, Co-Founder, President and &hellip; Continue reading &quot;BlossomHill Therapeutics Closes $71M Series A Financing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-03T21:04:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BlossomHill Therapeutics Closes $71M Series A Financing\",\"datePublished\":\"2021-03-03T21:04:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/\"},\"wordCount\":387,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/\",\"name\":\"BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\",\"datePublished\":\"2021-03-03T21:04:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/blossomhill-therapeutics-closes-71m-series-a-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlossomHill Therapeutics Closes $71M Series A Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/","og_locale":"en_US","og_type":"article","og_title":"BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk","og_description":"SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) &#8212; BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised\u00a0$71 million\u00a0in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company&#8217;s Board of Directors.\u00a0\u00a0 &#8220;Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,\u201d said\u00a0Dr. J. Jean Cui, Co-Founder, President and &hellip; Continue reading \"BlossomHill Therapeutics Closes $71M Series A Financing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-03T21:04:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BlossomHill Therapeutics Closes $71M Series A Financing","datePublished":"2021-03-03T21:04:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/"},"wordCount":387,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/","name":"BlossomHill Therapeutics Closes $71M Series A Financing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=","datePublished":"2021-03-03T21:04:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4MzkyOSM0MDQ3MDQ0IzIyMDc1NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/blossomhill-therapeutics-closes-71m-series-a-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BlossomHill Therapeutics Closes $71M Series A Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=449959"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/449959\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=449959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=449959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=449959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}